2017-03-27 0
On April 20, 2017, at the internal exchange meeting "Meet in Hangzhou, Plan for the Future" hosted by Huagai Medical Zhejiang Fund, guests from many early medical companies, Industrial and Commercial Bank of China, investment institutions, medical media and core team members of Huagai Medical shared their exclusive experiences and discussed these issues. Zhang Chenghai, Chairman of Shanghai Mabgeek, shared a series of experiences and insights in the development of biological drugs. He said that the development characteristics of biological drugs determine its three high characteristics of high investment, high risk and high return. Often, a blockbuster drug will leverage a market of tens of billions of dollars when it is launched, but a lot of clinical development is often required in the early stage, and it also faces a high risk of clinical failure. Therefore, Shanghai Mabgeek’s main appeal now is on the one hand, sufficient funds, and on the other hand, it hopes to have more cooperation with all walks of life to avoid some minefields in the early stage of biological drug development as much as possible.
All Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com